<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26712">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01872715</url>
  </required_header>
  <id_info>
    <org_study_id>GLI.04.SPR.US10233</org_study_id>
    <nct_id>NCT01872715</nct_id>
  </id_info>
  <brief_title>Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea</brief_title>
  <official_title>Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma Laboratories, L.P.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma Laboratories, L.P.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize rosacea patients', being treated with Oracea,
      perception through visual analog scale reporting.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Rosacea score on the Visual Analog Scale</measure>
    <time_frame>up to  week 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinician's Erythema Assessment</measure>
    <time_frame>baseline, week 2, week 6, and week 12 (exit)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigator Global Assessment of Rosacea scores</measure>
    <time_frame>baseline, week 2, week 6, and week 12 (exit)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient's Self Assessment of redness</measure>
    <time_frame>baseline, week 2, week 6, and week 12 (exit)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rosacea-Specific Quality of Life Index</measure>
    <time_frame>baseline, week 2, week 6, and week 12 (exit)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Papulopustular Rosacea</condition>
  <arm_group>
    <arm_group_label>Oracea</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oracea (doxycycline USP, 40mg[30mg immediate release/ 10mg delayed release beads] taken once daily in the morning on an empty stomach, one hour before meals or two hours after.
Oral dose for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oracea</intervention_name>
    <arm_group_label>Oracea</arm_group_label>
    <other_name>doxycycline USP, 40 mg (30 mg immediate release/ 10 mg delayed release beads)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women

          -  25-70 years

          -  Diagnosis of papulopustular rosacea

          -  Eligible for Oracea treatment

        Exclusion Criteria:

          -  Allergies to components of investigational product and/or hypersensitivity to
             tetracyclines

          -  Taken systemic therapy directed at improving rosacea, including antibiotics, within
             30 days prior to baseline visit

          -  Used topical rosacea treatment within 30 days prior to baseline visit

          -  Have active ocular rosacea and/or blepharitis/meibomianitis requiring systemic
             treatment by an opthalmologist

          -  Previously failed to have improvement of rosacea with appropriate use of systemic
             tetracycline family of antibiotics

          -  Exposed to intense/excessive ultraviolet (UV) radiation within one week prior to
             baseline and/or who forsee unprotected and intense/excessive UV exposure during the
             course of the study

          -  Have planned surgical procedures during the course of the study

          -  Have used tetracycline antibiotics within 30 days prior to baseline visit or during
             study

          -  At risk in terms of precautions, warnings, and contraindications
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stephens &amp; Associates Dallas Research Center</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <zip>75006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>July 1, 2013</lastchanged_date>
  <firstreceived_date>March 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Papulopustular Rosacea</keyword>
  <keyword>Oracea</keyword>
  <keyword>anti inflammatory doxycycline</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Doxycycline hyclate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
